Breaking News

AGC Biologics to Open New Manufacturing Site in Japan

Will offer preclinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA.

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), will construct a new manufacturing facility at AGC’s Yokohama Technical Center in Japan. The new site is part of the CDMO’s strategic growth strategy to create more high-quality pharmaceutical development and manufacturing services in the Asia region that can help meet the global demand for biologics and advanced therapy medicinal products (ATMPs). The facility is expected to be operational i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters